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comorbidities but the patterns vary considerably across patients. Although most 
diabetes guidelines address co-management of hypertension and 
hyperlipidemia, this MCC subgroup accounts for only one-fifth of patients. The 
development of evidence-based strategies to manage MCCs would help 
physicians and patients prioritize therapies and goals.  
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ASSESSING THE CLINICAL AND ECONOMIC BURDEN OF VETERAN DIABETES 
PATIENTS IN THE UNITED STATES  
Wang L1, Huang A1, Baser O2 
1STATinMED Research, Dallas, TX, USA, 2STATinMED Research/The University of Michigan, 
Ann Arbor, MI, USA  
OBJECTIVES: To assess the clinical characteristics and economic burden of  
type-2 diabetes patients in the U.S. veteran population METHODS: A 
retrospective database analysis was performed using the Veterans Health 
Administration (VHA) Medical SAS Datasets from October 1, 2005 to May 31, 2012. 
All U.S. veteran beneficiaries diagnosed with type-2 diabetes were identified 
using International Classification of Disease 9th Revision Clinical Modification 
(ICD-9-CM) diagnosis code 250.x0 or 250.x2. Comorbidities and other clinical 
conditions were examined for the 12-month baseline period. Health care 
resource utilization and costs were assessed for the 12-month follow-up period. 
Descriptive statistics were calculated as means ± standard deviation  
and percentages to measure comorbidities, laboratory results, costs, and 
utilization distribution within the sample. RESULTS: A total of 741,406 veterans 
were identified as diagnosed with Type 2 diabetes. Of these patients, 18.77%  
had glycated hemoglobin (HbA1c) test results ≥7% and 27.21% had abnormal 
serum creatinine results. 62.71% of patients were obese with a body mass index 
(BMI) of ≥30. The most common comorbidities were unspecified essential 
hypertension (21.62%), other and unspecified hyperlipidemia (6.75%) and post-
traumatic stress disorder (5.15%). After examining treatment within 60 days of 
disease identification, simvastatin was the most commonly prescribed 
medication (21.62%), followed by metformin hydrochloride (27.43%). Insulin was 
also among the top 10 treatments with 10.67% of patients prescribed this 
medication. The percentage of patients with follow-up outpatient visits was 
99.80%, which translated into $6,531 average outpatient costs. The percentages 
of inpatient (13.21%), emergency room (16.94%), physician office (99.76%) and 
pharmacy visits (90.33%) were also calculated for diabetes patients. 
CONCLUSIONS: Obesity may play an important role in patients' development of 
diabetes since two-thirds of studied patients were obese prior to disease 
identification. Hypertension may also be an associated risk factor that should be 
further evaluated.  
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OBJECTIVES: The ADA/EASD guidelines suggest the management and treatment 
of type 2 diabetes mellitus (T2DM) can be impacted by many factors such as age, 
comorbidities, hypoglycemia risk, and treatment adherence. Understanding  
how the T2DM disease burden differs across race/ethnic groups may aid  
in individualization of treatment. METHODS: Using data from the 2011 patient-
reported US National Health and Wellness Survey (NHWS), we characterized the 
T2DM population by profiling patients by race/ethnicity (White, African 
American [AA], Hispanic, or Other). NHWS results were stratified, then weighted 
and projected to reflect the demographic composition of the total adult 
population (based on Census data for gender, age, race/ethnicity, and 
educational attainment). RESULTS: Of the total 7,828 patients with T2DM, 75.8% 
were White, 11.4% were AA, 6.7% were Hispanic, and 6.1% were Other (includes 
Asian American and American Indian). The top 3 comorbidities per group  
were the same for the 3 predominant groups: hypertension (62% Whites, 64% 
AAs, 55% Hispanics), high cholesterol (66% Whites, 58% AAs, 57% Hispanics), and 
pain (55% Whites, 50% AAs, 51% Hispanics). However, significantly more Whites 
reported high cholesterol than AAs and Hispanics (P=0.002 and P=0.001, 
respectively). Sixty three to seventy nine percent of White, AA, and Hispanic 
patients with T2DM reported body mass index (BMI) ≥30 kg/m2; <10% of  
all patients reported BMI <25 kg/m2. Furthermore, Hispanics reported lower 
medication adherence than Whites (57.4% vs 65% adherent; P=0.008); adherence 
among AAs was 63%. Hypoglycemia was reported by 54% of Hispanics, 51%  
of Whites, and 49% of AAs. CONCLUSIONS: Understanding the characteristics of 
patients with T2DM by race/ethnicity can provide insights on the types  
of diabetes management challenges that different patient populations may  
face. These observations may encourage providers to engage minority 
populations in their health care management and tailor education to the 
individual.  
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DOES DEVICE MATTER AND AT WHAT COST? REAL-WORLD COMPARATIVE 
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Cao Z1, Thomson E1, Ling Z2, Miao R3, Wei W4 
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OBJECTIVES: For insulin-treated patients with type 2 diabetes mellitus (T2DM), 
disposable pen may facilitate insulin administration compared to traditional 
vial/syringe. This study compared real-world outcomes of insulin glargine (GLA) 
administered via disposable pen versus vial/syringe injections among Medicaid 
T2DM patients. METHODS: Using 2007-2010 claims data from the 
MarketScan®Medicaid database, this retrospective study examined 1-year follow-
up outcomes among adult T2DM patients who were insulin-naive and initiated 
GLA via disposable pen (Pen Initiators, PI) or vial/syringe (Vial Initiators, VI), or 
GLA users continuing vial/syringe (Vial Continuers, VC) or switching to 
disposable pen (Pen Switchers, PS). Propensity-score matching was used to 
control for differences in baseline characteristics between PI and VI cohorts, and 
PS and VC cohorts, with each pen user matched to ≤2 vial users. Endpoints 
included 1-year treatment persistence and adherence, hypoglycemia, and health 
care costs. RESULTS: There were 2594 matched patients from 7 states and 2 
managed care plans in the insulin-naive cohorts (PI: n=983, VI: n=1,611; mean 
age 56 years, 65% female) and 2237 matched patients in the insulin-experienced 
cohorts (PS: n=783, VC: n=1454; mean age 52 years, 66% female). Compared with 
their respective matched cohorts, pen cohorts were significantly more 
treatment-persistent (PI: 49.2% vs. VI: 40.8%; PS: 45.6% vs. VC: 36.7%; both 
P<0.001) for longer time (276 vs. 247 and 257 vs. 236 days; both P<0.001). Similar 
numbers of patients had hypoglycemia among the insulin-naive (P=0.153) and 
insulin-experienced cohorts (P=0.164). Although pen users had significantly 
higher study drug costs than vial users (P<0.001), total health care costs were 
comparable (PI: $15,151 vs. VI: $15,994; P=0.458, and PS: $22,441 vs. VC: $22,403; 
P=0.984) due to an offset of medical costs. CONCLUSIONS: This real-world study 
suggests that, among Medicaid T2DM patients treated with GLA, use of 
disposable pen provides a beneficial effect of achieving better persistence 
without increasing overall health care costs.  
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OBJECTIVES: Patients with type-1 diabetes (T1D) can either use multiple daily 
injections or insulin pump therapy (IPT) to achieve glycemic control. However, 
there is a lack of real-world data on the differences in these treatment options, 
particularly as they relate to effectiveness. The objective of this study was to 
investigate the relationship between IPT and HbA1c among patients with T1D. 
METHODS: Data from unique respondents from the 2009-2012 U.S. National 
Health and Wellness Surveys were used. Among respondents who reported a 
diagnosis of T1D and reported using insulin, those who reported using IPT were 
compared with those who were not using IPT on reported HbA1c levels using an 
ordered logistic regression model controlling for sociodemographic and health 
history differences. RESULTS: A total of 1833 patients reported being diagnosed 
with T1D and were currently using insulin. Of these patients, 495 reported using 
IPT (27.0%). Patients using IPT had been diagnosed with T1D for longer (26.8 vs. 
21.1 years) and were significantly more likely to be female (53.1% vs. 42.5%), be 
non-Hispanic white (85.9% vs. 68.3%), have an annual household income of $75K 
or more (28.3% vs. 19.2%), and possess health insurance (95.8% vs. 84.5%) (all 
p<.05). Patients using IPT also reported significantly lower levels of HbA1c (7.2% 
vs. 7.5%, p<.05). Adjusting for sociodemographic and health history differences, 
patients using IPT were significantly less likely to report HbA1c levels 9% or more 
(b=-0.80, OR=0.45, p<.05). CONCLUSIONS: Although T1D patients with greater 
health care access were more likely to use IPT, even after adjusting for these 
differences, a significant effect of IPT was observed on HbA1c. These results 
suggest that IPT may be associated with greater real-world effectiveness, though 
additional research is necessary.  
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REVIEW AND META-ANALYSIS OF RANDOMISED CONTROLLED CLINICAL 
TRIALS  
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OBJECTIVES: To perform a meta-analysis of the clinical and biochemical 
outcomes of N-Acetyl Cysteine (NAC) in women with polycystic ovary syndrome 
(PCOS). METHODS: Systematic review of pertinent studies was conducted by 
using bibliographic databases such as MEDLINE (Ovid), CENTRAL, EMBASE and 
PsycInfo(inception to Nov 2012). References of selected articles were either hand-
searched and by using PROQUEST and Web of Science. The review included 
randomised controlled trials with women participants having PCOS and 
undergoing treatment with NAC alone or in combination with ovulation 
induction methods like clomiphene citrate (CC) or gonadotropin injections, or in 
vitro fertilization (IVF). RESULTS: Out of 182 retrieved reports, eight studies (900 
women) were included. Three studies compared NAC (n=179) to metformin 
(n=177) while five studies compared NAC (n=272) to placebo (n=269). Compared 
to placebo, NAC improved pregnancy rate (pooled odds ratio, OR: 3.97, 95%  
CI: 2.07, 7.59, 3 trials, 377 women, P<0.0001; I2: 53%), ovulation rate (OR: 4.49, 95% 
CI: 2.86, 7.04, 3 trials, 353 women, P<0.0001; I2: 85%) and live birth rate (OR: 3, 95% 
CI: 1.05, 8.60, 1 trial, 60 women, P=0.04). However, compared to metformin, NAC 
did not improve pregnancy rate, resumption of menstruation cycle, body mass 
index or testosterone level. NAC was signifianctly associated with lower 
ovulation rate (OR: 0.13, 95% CI: 0.08, 0.22, 2 trials, 253 women, P<0.0001; I2: 0%) 
compared to metformin. On the other hand, compared to NAC, metformin 
improved glucose and insulin resistance profiles. Also, when used alone or in 
combination with clomiphene, NAC did not significantly improve the 
anthropometric characteristics, testosterone levels, and lipid profiles compared 
to placebo and metformin. CONCLUSIONS: NAC was associated with improved 
clinical pregnancy but there was limited evidence that NAC improved live birth 
rates alone or in combination with clomiphene. Given the quality of studies, 
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these findings require further confirmation to establish the role of NAC in 
improving reproductive outcomes in women with PCOS.  
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COMPARISON OF RISK OF TIME TO DEVELOPING DIABETES OF SMOKING 
CESSATION MEDICATIONS AMONG OBESE SMOKERS  
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OBJECTIVES: Recent literature suggests an increased risk of diabetes following 
smoking cessation. Our objective was to compare the risk of developing diabetes 
among obese smokers using bupropion versus varenicline as well as other 
predictors during the first 3 years post-cessation. METHODS: A population-based 
retrospective cohort study was conducted using the General Electric (GE) 
electronic medical record database (2006 – 2011). The cohort consisted of obese 
adult smokers newly initiating use of a smoking cessation medication: 
bupropion versus varenicline without a diabetes diagnosis at baseline. The 
outcome variable was time to developing diabetes following first prescription 
with a 3-year follow up. Chi-square tests were conducted to assess the frequency 
distribution of sample characteristics and association with diabetes 
development. Univariate survival analyses using Kaplan-Meier survival curve 
were conducted and log-rank test was used to assess significance. Cox 
Proportional Hazard (PH) regression model was carried out after evaluating PH 
assumption by Schoenfeld residual test. Interaction terms were included in the 
PH regression model if assumption was violated. RESULTS: The sample 
comprised of 91,899 individuals. A total of 3,668 (crude diabetes incidence rate: 
13.3 per 1,000 person-years) obese smokers developed diabetes in 3 years. 
Abstinence at 12 months did not meet the PH assumption and interaction was 
created for this variable in the final Cox model. There was no statistically 
significant difference in diabetes risk using bupropion versus varenicline (Hazard 
Ratio: 1.408 95% Confidence Interval: 0.963 - 2.058). Non-primary care group 
(1.271 [1.069 – 1.511]), male (1.174 [1.004 – 1.373]), non-white (1.197 [1.015 – 1.410]), 
age group (40 – 64) (0.803 [0.656 – 0.984]), abstinence at 12 months (0.758 [0.604 – 
0.952]), hypertension (1.239 [1.017 – 1.509]),and lung cancer (2.023 [1.024 – 3.999]) 
were significant predictors of developing diabetes. CONCLUSIONS: There is no 
significant difference in the diabetes risk three years post-cessation among 
obese adults using varenicline versus bupropion.  
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A COMPARISON OF BIPHASIC INSULIN ASPART (BIASP30) WITH BIPHASIC 
HUMAN INSULIN (BHI30) FOR TYPE 2 DIABETES MELLITUS IN REAL CLINICAL 
PRACTICE – A SYSTEMATIC REVIEW AND META-ANALYSIS  
Wojciechowski P1, Gaweska M1, Caban A1, Jurkiewicz B2, Plisko R1, Rys P1 
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OBJECTIVES: Both biphasic human insulin 30 (BHI30) and biphasic insulin aspart 
(BIAsp30) serve an effective treatment option in patients with T2DM and their 
relative efficacy has been investigated in randomized clinical trials (RCTs). The 
aim of our analysis was to compare efficacy and safety of BIAsp30 with BHI30 on 
the basis of non-interventional trials. METHODS: Systematic search in PubMed, 
Medline and CENTRAL was carried out until November 2011. Non-interventional 
trials comparing either BIAsp30 with BHI30 in a parallel design or assessing a 
replacement therapy with one insulin preparation after suboptimal response to 
the other were included. RESULTS: Eight studies met the inclusion criteria; three 
compared directly BIAsp30 with BHI30, five assessed BIAsp30 after suboptimal 
treatment with BHI30. No studies evaluating BHI30 after BIAsp30 were identified. 
Meta-analysis of parallel studies demonstrated superiority of BIAsp30 over BHI30 
with respect to the reduction of HbA1c (3 studies; WMD = -0.16% [-0.24; -0.08]) 
without increased risk of hypoglycemic episodes. Switching from BHI30 to 
BIAsp30 was associated with noticeable improvement in HbA1c level (3 studies; 
WMD = -1.69% [-1.94; -1.45]), fasting glucose (2 studies; -3.20 mmol/l [-3.75; -2.65]) 
and post-prandial glucose level (2 studies; WMD = -4.66 mmol/l [-4.74; -4.58]). The 
largest study demonstrated that the use of BIAsp30 instead of BHI30 revealed 
statistically significant reduction in the incidence of both minor (MD = -5.7 
episodes/patient/year; p<0.0001) and major hypoglycemic episodes (MD = -0.331; 
p<0.0001). BIAsp 30 was not associated with a weight gain either in parallel 
design nor in studies assessing sequential treatment. CONCLUSIONS: In this 
analysis, including real clinical practice studies BIAsp30 was more effective than 
BHI30 in the control of T2DM. Additionally, BIAsp30 was a good alternative for 
patients with failure or suboptimal response to previous insulin therapy with 
BHI30.  
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SOCIAL NETWORKS BOOST DIABETES EDUCATION AND REDUCE HBA1C AND 
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OBJECTIVES: The goal of the “Diabetes Peer to Peer (P2P®) Study” was to assess 
the effect of social networks for diabetes information sharing on the 
improvement of diabetes management in patients with type 2 diabetes in the 
Baltimore metropolitan area. METHODS: In this prospective cohort study 
enrolling patients with diabetes, those in the intervention group (P2P®) were 
asked to recruit peers, form small groups, and attend monthly diabetes 
education sessions, emphasizing peer-support. Patients in the control group 
were recruited individually to attend standard diabetes education sessions. The 
primary outcomes were changes in Hemoglobin A1C (HbA1c) and blood glucose. 
Secondary outcomes included clinical indicators (blood pressure, BMI), 
functional status, self-efficacy, perceived cohesion, social network 
connectedness, and diabetes knowledge. Socio-demographics, drug history, and 
comorbidities were also recorded. Multivariate regression models, finalized after 
a stepwise selection process, were built to assess mean absolute changes in 
HbA1c and blood glucose at the first follow-up, at three months. RESULTS: Of a 
total of 136 enrolled, the intervention patients (68) had more metformin use, 
higher BMI, lower social network scores, and lower diabetes knowledge at 
baseline. All other baseline characteristics were evenly distributed between 
arms. At follow-up, P2P® patients had a larger reduction in HbA1c (-0.47 vs.  
-0.31%, P=0.17) and blood glucose (-9.1 vs. -2.4 mg/dL, P=0.05) than the controls. 
In multivariate adjusted models, P2P® was associated with a statistically 
significantly larger mean reduction in HbA1c (-0.33%, P<0.01) and blood glucose (-
8.6 mg/dL, P<0.01), than the control. Marital status, insulin use, high baseline 
Hba1c, and good physical functional status were associated with a significant 
drop in Hba1c and blood glucose. CONCLUSIONS: The social networks, as 
opposed to the individual approach to diabetes education, prove more effective 
at reducing patients’ HbA1c and blood glucose at 3-months follow-up.  
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COMPARATIVE STUDY OF INITIATION OF BASAL ANALOG INSULIN AND 
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OBJECTIVES: To compare real-world outcomes among Medicaid patients with 
type 2 diabetes mellitus (T2DM) initiating insulin glargine (GLA) or insulin 
detemir (DET). METHODS: Using the MarketScan®Multi-State Medicaid claims 
database, this retrospective study examined T2DM patients aged ≥18 years who 
were previously insulin-naive and initiated GLA or DET between 2006 and 2009. 
All patients had continuous Medicaid coverage for ≥6 months before (baseline) 
and ≥12 months after GLA or DET initiation. Stringent propensity-score matching 
was used to balance DET with GLA patients, and a subgroup of disposable-pen 
users in both groups, on baseline characteristics. Endpoints included 1-year 
follow-up treatment persistence and adherence, hypoglycemia rates, and health 
care costs. RESULTS: Included in the main analysis were 1,354 DET users, 
matched with 1:up to 2 ratio to 2,573 GLA users from 11 states/health plans 
(mean age 53 years; 71% female). In the subanalysis of disposable-pen users, 548 
from each group were 1:1 matched (mean age 55 years; 70% female). Compared 
with DET users, GLA users were more treatment-persistent (main analysis 
[subanalysis]: 44.2% versus 47.2% [46.7% vs. 54.2%]; P=0.071 [P=0.015]), had more 
persistent days (257 vs. 266 [267 vs. 287] days; P=0.008 [P<0.001]), and were more 
adherent (adjusted medication possession ratio 61.1% vs. 65.0% [61.4% vs. 66.7%]; 
P<0.001 [P=0.006]). Hypoglycemia rates were similar for both groups (10.8% vs. 
10.7% [11.1% vs. 8.9%]; P=0.957 [P=0.225]). Det patients incurred higher diabetes-
related outpatient ($2,198 vs. $1,942 [$2,252 vs. $2,067]; P=0.038 [P=0.418]) and 
drug costs ($1,570 vs. $1,397 [$1,432 vs. $1,338]; P=0.002 [P=0.400]), although 
overall costs were similar ($20,371 vs. $21,210 [$15,847 vs. $15,883]; P=0.548 
[P=0.985]). CONCLUSIONS: This study suggests that initiating GLA in T2DM 
Medicaid patients was associated with better treatment persistence and 
adherence than DET. However, the findings are exploratory, limited by their 
retrospective nature and the lack of key clinical data such as A1C.  
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OBJECTIVES: To compare the outcomes of a cohort of children born small  
for gestational age and/or with intrauterine growth retardation (SGA/IUGR) 
treated with growth hormone (GH) in Colombia with a global cohort from KIGS 
(Pfizer International Growth Database) population of the same characteristics 
(Ranke et al, 2010), over 1 and 2 years. METHODS: Two Colombian children 
cohorts, diagnosed with SGA/IUGR and treated with GH, included in KIGS, were 
assessed: cohort 1 (n=39) with 1-year follow-up and cohort 2 (n=16) with 2-year 
follow-up. The cohort characteristics (clinical outcomes in Standard Deviation 
Score (SDS) for height, weight, body mass index, and growth rate [cm/year]) were 
described at the time of initiation of therapy and at 1 and 2 years follow-up,  
and were compared with children from the global cohort. RESULTS: Cohort 1 
began treatment at 6.63 years (average) with a height of -3.20 SDS and weight of -
2.42 SDS, growth rate reported after one year of treatment was 0.22cm lower 
than the global cohort (8.18 vs 8.4 cm/yr respectively); Cohort 2 with, began 
treatment at 5.28 years (average) with a height of -3.83 SDS and a weight of -3.73 
SDS; reported growth rate was 0.27 cm lower than the global cohort in the 1-year 
follow-up and 0.63 cm over the 2-year follow-up (8.23 vs. 8.5 and 7.63 vs. 7.00 
cm/year respectively). Regarding the height difference (SDS), cohort 1 was 0.12 
SDS lower than the global cohort (0.58 vs. 0.7) and cohort 2 was 0.2 SDS lower 
than the first year of follow-up and 0.05 SDS higher than the 2 year follow-up (0.5 
vs. 0.7 and 0.45 vs. 0.4, respectively). CONCLUSIONS: This analysis demonstrates 
that GH administration has a positive effect on height in children diagnosed 
SGA/IUGR in Colombia; they respond to therapy similarly to a globally treated 
cohort.  
